Table 1 Demographic and biological characteristics of patient cohorts.

From: Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

  Normal Median (range) P a
range Australian cohort Dutch cohort
Number of patients   61 35  
Ancestry
   European   43 (70.5%) 35 (100%)  
   Asian   14 (23.0%) 0 (0.0%)  
Others   4 (6.6%) 0 (0.0%)  
Treatment
   Carboplatin + paclitaxel   55 (90.2%) 35 (100%)  
   Carboplatin only   6 (9.8%) 0 (0.0%)  
Pharmacokinetic sampling
   Cycle 1   61 (100%) N/Ab  
   Cycle 3c   7 (11.5%)   
Age   56 (19–74) 57 (38–74)  
Height (cm)   161 (148–174) 167 (150–179) 0.918
Weight (kg)   64 (36–120) 75 (53–111) 0.015
Total bilirubin (µmol/L) ≤20 6 (2–13) 6 (6–13) 0.430
Albumin (g/L) 35–50 40 (20–49) N/Ad N/A
Alanine amino transaminase (U/L) ≤47 28 (6–159) 22 (7–55) 0.779
Aspartate amino transaminase (U/L) ≤45 40 (14–242) 24 (17–45) 0.016
Creatinine (µmol/L) 55–105 60 (42–165) 69 (45–118) 0.002
Glomerular filtration rate (mL/min) 90–120 80 (22–143) 70 (36–107) 0.003
  1. aP-values were based on independent sample median test.
  2. bPaclitaxel sampling was performed in different treatment cycles in the Dutch cohort.
  3. cSeven patients had carboplatin and paclitaxel sampling performed during both cycle 1 and cycle 3.
  4. dAlbumin level results were available from only eight patients in the Dutch cohort.